中枢神经系统血管母细胞瘤35例临床分析  

Central Nervous System Hemangioblastoma:An Analysis of 35 Cases

作　　者：黄永安[1] 程钢戈[1] 张宝国[1] 董连强[1] 周岩[1] 张晖[1] 舒成[1] 

机构地区：[1]中国人民解放军空军总医院神经外科,北京100142

出　　处：《南昌大学学报（医学版）》2013年第4期60-63,共4页Journal of Nanchang University：Medical Sciences

摘　　要：目的探讨中枢神经系统血管母细胞瘤的发病机制、临床特点及治疗方法。方法回顾性分析中国人民解放军空军总医院自1995年2月至2011年12月收治的35例血管母细胞瘤患者的临床资料。结果术后随访9个月～11年,平均3.7年。本组35例患者术后有6例复发(占17.1%),其中4例行二次手术,2例给予伽玛刀放疗。所有病例完全和部分缓解29例(占82.9%),好转3例(占8.6%),稳定2例(占5.7%),进展1例(占2.8%)。结论显微外科手术切除加伽玛刀辅助放疗,目前仍然是治疗血管母细胞瘤的有效方法。Objective To investigate the pathogenesis,clinical features and treatment of central nervous system hemangioblastoma.Methods Clinical data of 35 hemangioblastoma patients admitted to Air Force General Hospital of the Chinese People’s Liberation Army from February 1995 to December 2011 were analyzed retrospectively. Results Patients were followed-up for an average of 3.7 years（range 9 months to 11 years）.Six（17.1%） of the 35 patients had postoperative recurrence.Among the 6 patients,the secondary operation was performed in 4 and gamma knife treatment in 2.Among the 35 patients,29（82.9%） achieved complete or partial remission,3（8.6%） achieved improvement,2（5.7%） had stable disease and 1（2.8%） had disease progression. Conclusion Microsurgical resection combined with gamma knife adjuvant therapy is still an effective treatment method for hemangioblastoma.

关 键 词：血管母细胞瘤 显微外科 伽玛刀放疗 

分 类 号：R739.41[医药卫生—肿瘤]